Poster Hall
Sponsored by AbbVie Medical Affairs
Conference Perspectives
View all perspectives
Mrinalini Dey DrMiniDey
3 months 1 week ago
#EULAR2024
Powerful quote to end @Dr_SBattista’s HPR highlights:
"People working together in a strong community with a shared goal and a common purpose can make the impossible possible"- Tom Vilsack
@RheumNow
Bella Mehta bella_mehta
3 months 1 week ago
Interdisciplinary collaboration is the key!
@rheumnow #EULAR2024 https://t.co/pARPUH2ntr
David Liew drdavidliew
3 months 1 week ago
Photos of hands/finger folds for RA disease activity - nice idea, challenges++, but with poor photo quality you’re always struggling.
Telehealth has taught us:
- ideal settings can work, but
- suboptimal inputs inevitably lead to suboptimal results
#EULAR2024 POS0451 @RheumNow https://t.co/fyCQzSl6tB
Bella Mehta bella_mehta
3 months 1 week ago
placebo effects can be huge!
#EULAR2024 @RheumNow https://t.co/RmcBAPG2Ye
Mrinalini Dey DrMiniDey
3 months 1 week ago
Fantastic speakers, chairs and faculty for the #PARE session on self-management.
#EULAR2024 @RheumNow https://t.co/9ulRWL2Mnp
Mrinalini Dey DrMiniDey
3 months 1 week ago
#EULAR2024 highlights
@Dr_SBattista discusses the beneficial effects of exercise for inflammation and general well-being, presented by Prof Kitas
@RheumNow https://t.co/WAHg4ub8R3
David Liew drdavidliew
3 months 1 week ago
Have RA and want to get pregnant? What can you do?
The answer is simple: disease control.
Implementing T2T in RA led to much better fertility. RA therapy is your friend!
#EULAR2024 POS0436 Rotterdam @RheumNow https://t.co/aoxNakMix1
Peter Nash drpnash
3 months 1 week ago
OP0007 (2024)
S/C ABA VS ADA H2H COMPARISON ADULTS EARLY, DUAL SEROPOSITIVE RA, +ive FOR SHARED EPITOPE HLA CLASS II RISK ALLELES, & INADEQUATE RESPONSE TO MTX: RESULTS FROM PH3 AMPLIFIED TRIAL shame seropositivity did not translate to an advantage for AbA @RheumNow #EULAR2024
Bella Mehta bella_mehta
3 months 1 week ago
PARE summary at #EULAR2024 - love the word cloud highlighting the posters @RheumNow
RA, SLE and JIA were the key RMDs that were focused on. By Silvia Aguleria https://t.co/WbSKwE6vXs
Md Yuzaiful Md Yusof Yuz6Yusof
3 months 1 week ago
#EULAR2024 POS0375 Negative trial need to be reported too. Phase 2 RCT of S95011, an IL7-R antibody in moderate to severe systemic #Sjogren failed to meet primary endpoint (ESSDAI) or other secondary (ESSPRI, biomarkers). This inhibition unlikely to impact on SjD @RheumNow
Bella Mehta bella_mehta
3 months 1 week ago
EULAR PARE highlights
- Need close collaboration between patients and physicians.
-Child to adult transition need to be smooth to be successful (30% patients can be lost in transitions)
- We need patients to participate in Health Technology Assessment
@rheumnow #EULAR2024 https://t.co/50qFpRGXo2
Aurelie Najm AurelieRheumo
3 months 1 week ago
Another proof (if needed) that controlling DA in RA is a very important preventive measure in RA!
179 pts
ILD newly developed 9.5%
progressed 12.3%
no change 74.9%
improved 4.5%
5.7% in the LDA group 28.0% non-LDA group (p=0.006)
@RheumNow #EULAR2024 POS0408 https://t.co/7DyXr5zdCM
Peter Nash drpnash
3 months 1 week ago
POS0061 (2024)
INTERCEPTION OF THE DEVELOPMENT OF RA BY 1-YEAR MTX IN ACPA-NEGATIVE ARTHRALGIA PATIENTS AT INCREASED RISK FOR RA: 4 YEAR RESULTS OF THE TREAT EARLIER TRIAL MTX reduced development of RA in high risk acpa neg pts https://t.co/XWnzuVMlbn @RheumNow #EULAR2024
Aurelie Najm AurelieRheumo
3 months 1 week ago
T2T strategy in RA during pregnancy improves time to procreate
Results PreCARA (T2T median DAS28CRP 2.33) vs. PARA median DAS28CRP 3.84)
median TTP 84d vs. 196d
TTP exceeded 12 months in 23% of PreCARA pts compared to 42% in the PARA pts.
@RheumNow #EULAR2024 POS0436 https://t.co/DfgEvvtCwR
Peter Nash drpnash
3 months 1 week ago
RISK OF NON-MELANOMA SKIN CANCER WITH TNFi AND OTHER bDMARDs IN PATIENTS WITH PSORIATIC ARTHRITIS: A SWEDISH AND DANISH COHORT STUDY- despite having minimal sun 25% increase NMSC TNFis vs other bDMARDs - skin checks ! @RheumNow #EULAR2024
